Canadian consensus guidelines for the management of testicular germ cell cancer

Journal of the Canadian Urological Association

Volumn 4, Issue 2, 2010, Pages

  Wood, Lori ^a   Kollmannsberger, Christian ^b   Jewett, Michael ^c   Chung, Peter ^d   Hotte, Sebastian ^e   O'Malley, Martin ^c   Sweet, Joan ^c   Anson Cartwright, Lynn ^d   Winquist, Eric ^f   North, Scott ^g   Tyldesley, Scott ^h   Sturgeon, Jeremy ⁱ   Gospodarowicz, Mary ^d   Segal, Roanne ^j   Cheng, Tina ^b   Venner, Peter ^g   Moore, Malcolm ^k   Albers, Peter ^l   Huddart, Robert ^m   Nichols, Craig ⁿ   Warde, Padraig ^d   more..

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g CROSS CANCER INSTITUTE   (Canada)

^h Vancouver Clinic   (Canada)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j OTTAWA REGIONAL CANCER CENTRE   (Canada)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951177381     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Article

References (195)

1. International Agency for Reseach on Cancer. World Health Organization. Available at: http://www-dep.iarc.fr/. Accessed March 9, 2010.
2. McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97:63-70.
3. Canadian Cancer Society. Available at: www.cancer.ca. Accessed March 17, 2010.
4. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91:839-46.
5. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99.
6. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008;53:478-96.
7. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008;53:497-513.
8. Richie JP. Impact of diagnostic delay in testis cancer: Results of a large population-based study: Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P, Human Fertility Research Group, Paule de Viguier Hospital, Toulouse University III, France; Urology and Andrology Department, Paule de Viguier Hospital, Toulouse, France. Urol Oncol 2008;26:220-1.
9. th ed. Hoboken, NJ: Wiley, John & Sons; 2002.
10. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
11. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818-26.
12. Winstanley AM, Mikuz G, Debruyne F, et al. Handling and reporting of biopsy and surgical specimens of testicular cancer. Eur Urol 2004;45:564-73.
13. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. Apmis 2003;111:76-83; discussion 83-75.
14. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42:553-62; discussion 562-3.
15. Horwich A, Alsanjari N, A'Hern R, et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992;65:775-8.
16. Oliver R, Boubilkova L, Ong J. Fifteen-year follow-up of the Anglian Germ Cell Cancer group adjuvant studies of carboplatin as an alternative to radiation or surveillance for stage 1 seminoma. Proc ASCO 2001;19 Abstract 780.
17. Ramakrishnan S, Champion AE, Dorreen MS, et al. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) 1992;4:284-6.
18. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931-4.
19. Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol 2005;23(16suppl):4520.
20. Tyldesley S, Voduc D, McKenzie M, et al. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology 2006;67:594-8.
21. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52.
22. Aparicio J, Germa JR, Garcia del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23:8717-23.
23. Bayens YC, Helle PA, Van Putten WL, et al. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother Oncol 1992;25:97-102.
24. Coleman JM, Coleman RE, Turner AR, et al. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol) 1998;10:237-41.
25. Fossa SD, Bokemeyer C, Gerl A, et al. Treatment outcome of patients with brain metastases from malignant germ cell tumours. Cancer 1999;85:988-97.
26. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-8.
27. Santoni R, Barbera F, Bertoni F, et al. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. BJU Int 2003;92:47-52; discussion 52.
28. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255-62.
29. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumour Working Group. J Clin Oncol 1999;17:1146.
30. Logue JP, Harris MA, Livsey JE, et al. Short course paraaortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 2003;57:1304-9.
31. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-23.
32. Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640-7.
33. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-24.
34. Moller H, Friis S, Kjaer SK. Survival of Danish cancer patients 1943-1987. Male genital organs. APMIS Suppl 1993;33:122-36.
35. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65.
36. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370-8.
37. Oliver RT, Ong J, Shamash J, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004;63:556-61.
38. Steiner H, Muller T, Gozzi C, et al. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int 2006;98:349-52.
39. Hotte S, Mayhew LA, Jewett M, et al. Cancer Care Ontario. Management of Stage I Nonseminomatous Testicular Cancer: Guideline Recommendations. Available at www.cancercare.on.ca/pdf/pebc3-19s.pdf. Accessed March 9, 2010.
40. Read G, Johnson RJ, Wilkinson PM, et al. Prospective study of follow up alone in stage I teratoma of the testis. Br Med J (Clin Res Ed) 1983;287:1503-5.
41. Sogani PC, Whitmore WF Jr, Herr HW, et al. Orchiectomy alone in the treatment of clinical stage I non- seminomatous germ cell tumour of the testis. J Clin Oncol 1984;2:267-70.
42. Pizzocaro G, Zanoni F, Milani A, et al. Orchiectomy alone in clinical stage I nonseminomatous testis cancer: a critical appraisal. J Clin Oncol 1986;4:35-40.
43. Peckham MJ, Brada M. Surveillance following orchidectomy for stage I testicular cancer. Int J Androl 1987;10:247-54.
44. Sturgeon JF, Jewett MA, Alison RE, et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumour s. J Clin Oncol 1992;10:564-8.
45. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumour s Working Party. J Clin Oncol 1992;10:1762-8.
46. Colls BM, Harvey VJ, Skelton L, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999;83:76-82.
47. Pont J, Holtl W, Kosak D, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumour: a prospective trial. J Clin Oncol 1990;8:16-20.
48. Klepp O, Dahl O, Flodgren P, et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997;33:1038-44.
49. Divrik RT, Akdogan B, Ozen H, et al. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumours-is shift to risk adapted policy justified? J Urol 2006;176(4 Pt 1):1424-9; discussion 1429-30.
50. Roeleveld TA, Horenblas S, Meinhardt W, et al. Surveillance can be the standard of care for stage I non- seminomatous testicular tumour s and even high risk patients. J Urol 2001;166:2166-70.
51. Alexandre J, Fizazi K, Mahe C, et al. Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001;37:576-82.
52. Francis R, Bower M, Brunstrom G, et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000;36:1925-32.
53. Sogani PC, Perrotti M, Herr HW, et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855-8.
54. Hao D, Seidel J, Brant R, et al. Compliance of clinical stage I nonseminomatous germ cell tumour patients with surveillance. J Urol 1998;160(3 Pt 1):768-71.
55. Boyer MJ, Cox K, Tattersall MH, et al. Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumours: late relapse may occur. Urology 1997;50:588-92.
56. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumours of the testis: 10-year followup. J Urol 1995;154:1045-9.
57. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I non- seminomatous testicular germ cell tumours and consequences for further follow-up: a single-center 10- year experience. J Clin Oncol 1995;13:1188-94.
58. Ondrus D, Hornak M. Orchiectomy alone for clinical stage I nonseminomatous germ cell tumours of the testis (NSGCTT): a minimum follow-up period of 5 years. Tumour i 1994;80:362-4.
59. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987;2:294-8.
60. Maroto P, Garcia del Muro X, Aparicio J, et al. Multicentre risk-adapted management for stage I non- seminomatous germ cell tumours. Ann Oncol 2005;16:1915-20.
61. Amato RJ, Ro JY, Ayala AG, et al. Risk-adapted treatment for patients with clinical stage I nonsemino- matous germ cell tumour of the testis. Urology 2004;63:144-8; discussion 148-9.
62. Ondrus D, Matoska J, Belan V, et al. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumour s: rationale for different risk-adapted treatment. Eur Urol 1998;33:562-6.
63. Rorth M, Jacobsen GK, von der Maase H, et al. Surveillance alone versus radiotherapy after orchiecto- my for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. J Clin Oncol 1991;9:1543-8.
64. Weissbach L, Boedefeld EA, Horstmann-Dubral B. Surgical treatment of stage-I non-seminomatous germ cell testis tumour. Final results of a prospective multicenter trial 1982-1987. Testicular Tumour Study Group. Eur Urol 1990;17:97-106.
65. Albers P, Siener R, Krege S, et al. Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumours: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008;26:2966-72.
66. Donohue JP, Thornhill JA, Foster RS, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993;149:237-43.
67. Sweeney CJ, Hermans BP, Heilman DK, et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 2000;18:358-62.
68. Nicolai N, Miceli R, Artusi R, et al. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumour s undergoing retroperitoneal lymph node dissection only. J Urol 2004;171:172-6.
69. Stephenson AJ, Bosl GJ, Bajorin DF, et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174:557-60; discussion 560.
70. Spermon JR, Roeleveld TA, van der Poel HG, et al. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumours. Urology 2002;59:923-9.
71. Dearnaley DP, Fossa SD, Kaye SB, et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high- risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 2005;92:2107-13.
72. Pectasides D, Skarlos D, Dimopoulos AM, et al. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res 2003;23:4239-44.
73. Bohlen D, Borner M, Sonntag RW, et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumours with high risk factors. J Urol 1999;161:1148-52.
74. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumours of the testis: a Medical Research Council report. J Clin Oncol 1996;14:1106-13.
75. Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441-8.
76. Oliver RT, Raja MA, Ong J, et al. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 1992;148:1453-5; discussion 1455-6.
77. Madej G, Pawinski A. Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis. Clin Oncol (R Coll Radiol) 1991;3:270-2.
78. Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage i nonseminomatous germ cell tumour. J Urol 2000;163:1785-7.
79. Chevreau C, Mazerolles C, Soulie M, et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumours with embryonal carcinoma and/or vascular invasion. Eur Urol 2004;46:209-14; discussion 214-5.
80. Gilbert DC, Norman AR, Nicholl J, et al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int 2006;98:67-9.
81. Westermann DH, Schefer H, Thalmann GN, et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumours of the testis. J Urol 2008;179:163-6.
82. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433-8.
83. Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumour. J Urol 1991;146:1295-8.
84. Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995;153:85-9.
85. Kennedy BJ, Torkelson JL, Fraley EE. Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis. Cancer 1994;73:1485-9.
86. Kuczyk M, Machtens S, Stief C, et al. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumours (NSGCT). Int J Cancer 1999;83:852-5.
87. Weissbach L, Bussar-Maatz R, Flechtner H, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumours? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582-94.
88. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 2007;25:5597-602.
89. Sheinfeld J, Motzer RJ, Rabbani F, et al. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumours. J Urol 2003;170(4 Pt 1):1159-62.
90. Horwich A, Stenning S. Initial chemotherapy for stage II testicular non-seminoma. World J Urol 1994;12:148-50.
91. Peckham MJ, Hendry WF. Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. Br J Urol 1985;57:763-8.
92. Logothetis CJ, Samuels ML, Selig DE, et al. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol 1985;134:1127-30.
93. Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathologic stage II non- seminomatous germ cell tumours of the testis. J Urol 1984;131:677-80.
94. Pizzocaro G, Piva L, Salvioni R, et al. Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumours of testis. In which cases is it necessary? Eur Urol 1984;10:151-8.
95. Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464-7.
96. Feuer EJ, Frey CM, Brawley OW, et al. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 1994;12:368-77.
97. Saxman SB, Finch D, Gonin R, et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumours: the Indian University experience. J Clin Oncol 1998;16:702-6.
98. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable- prognosis disseminated germ cell tumours: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-91.
99. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-40.
100. Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumours: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007;18:917-24.
101. Fossa SD, de Wit R, Roberts JT, et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003;21:1107-18.
102. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844-52.
103. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours: a multiinstitutional study. J Clin Oncol 1993;11:598-606.
104. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001;357:739-45.
105. Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumours: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-6.
106. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumours. J Clin Oncol 1988;6:1231-8.
107. Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumours treated with etoposide and cisplatin. J Clin Oncol 1997;15:2553-8.
108. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumours: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16:1287-93.
109. de Wit R, Collette L, Sylvester R, et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 1998;78:1350-5.
110. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78:828-32.
111. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumours. J Clin Oncol 2007;25:247-56.
112. Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007;51:739-46; discussion 747-8.
113. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
114. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poorprognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716-24.
115. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumour s and lymphomas. N Engl J Med 2005;353:988-98.
116. Cullen MH, Billingham LJ, Gaunt CH, et al. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007;25:4821-8.
117. Chong C, Logothetis CJ, von Eschenbach A, et al. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol 1986;136:1221-3.
118. Leibovitch I, Baniel J, Rowland RG, et al. Malignant testicular neoplasms in immunosuppressed patients. J Urol 1996;155:1938-42.
119. Ondrus D, Hornak M, Breza J, et al. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol 2001;32:665-7.
120. Simmonds PD, Mead GM, Lee AH, et al. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? Cancer 1995;75:1018-24.
121. Fossa SD, Stenning SP, Gerl A, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999;80:1392-9.
122. Andre F, Fizazi K, Culine S, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000;36:1389-94.
123. Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumour patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998;16:1294-7.
124. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumour in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993;11:1294-9.
125. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumours: recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
126. Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumours of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002;94:1668-76.
127. Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006;176:100-3; discussion 103-4.
128. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemothera-py for testis cancer. J Urol 1987;137:1176-9.
129. Debono DJ, Heilman DK, Einhorn LH, et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumours. J Clin Oncol 1997;15:1455-64.
130. Vergouwe Y, Steyerberg EW, de Wit R, et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 2003;88:843-7.
131. Steyerberg EW, Keizer HJ, Habbema JD. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer 1999;83:856-9.
132. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumour : multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177-87.
133. Vergouwe Y, Steyerberg EW, Foster RS, et al. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol 2007;51:424-32.
134. Oldenburg J, Alfsen GC, Lien HH, et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumour masses. J Clin Oncol 2003;21:3310-7.
135. Fossa SD, Ous S, Lien HH, et al. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989;141:557-9.
136. Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007;25:1033-7.
137. Hendry WF, A'Hern RP, Hetherington JW, et al. Paraaortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 1993;71:208-13.
138. Aprikian AG, Herr HW, Bajorin DF, et al. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumours. Cancer 1994;74:1329-34.
139. Wood DP Jr, Herr HW, Heller G, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumours. J Urol 1992;148:1812-5; discussion 1815-6.
140. Rabbani F, Goldenberg SL, Gleave ME, et al. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol 1998;81:295-300.
141. Beck SD, Foster RS, Bihrle R, et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumour ? Cancer 2007;110:1235-40.
142. Carver BS, Shayegan B, Eggener S, et al. Incidence of metastatic nonseminomatous germ cell tumour outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2007;25:4365-9.
143. Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumour patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998;83:1409-19.
144. Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995;153(3 Pt 2):976-80.
145. Rassweiler JJ, Frede T, Lenz E, et al. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37:251-60.
146. Janetschek G, Peschel R, Hobisch A, et al. Laparoscopic retroperitoneal lymph node dissection. J Endourol 2001;15:449-53; discussion 453-5.
147. Steiner H, Peschel R, Janetschek G, et al. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 2004;63:550-5.
148. Hartmann JT, Candelaria M, Kuczyk MA, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997;33:843-7.
149. Steyerberg EW, Donohue JP, Gerl A, et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Reanalysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 1997;158:474-8.
150. Tognoni PG, Foster RS, McGraw P, et al. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumour under the same anesthetic is appropriate based on morbidity and tumour pathology. J Urol 1998;159:1833-5.
151. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thoracotomy for postchemotherapy resection of pulmonary residual tumour mass in patients with nonseminomatous testicular germ cell tumours: aggressive sur-gical resection is justified. Chest 1997;112:967-73.
152. Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumours of the testis. J Clin Oncol 1996;14:1765-9.
153. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740-4.
154. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumour in postchemotherapy seminoma: an update of the prospec-tive multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9.
155. Albers P, Weissbach L, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumours: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004;171:1835-8.
156. Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860-2.
157. Ravi R, Ong J, Oliver RT, et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999;83:649-53.
158. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14:454-60.
159. Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int 1996;57:38-42.
160. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997;33:829-35.
161. Mosharafa AA, Foster RS, Leibovitch BC. Is the postchemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2002;167:172.
162. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 2001;19:2647-57.
163. Azar JM, Schneider BP, Einhorn LH. Is the blood-brain barrier relevant in metastatic germ cell tumour? Int J Radiat Oncol Biol Phys 2007;69:163-6.
164. Spears WT, Morphis JG 2nd, Lester SG, et al. Brain metastases and testicular tumour s: long-term survival. Int J Radiat Oncol Biol Phys 1992;22:17-22.
165. Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997;15:1449-54.
166. Hartmann JT, Bamberg M, Albers P. Multidisciplinary treatement and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. Proc Am Soc Clin Oncol 2003;22:400.
167. Kollmannsberger C, Nichols C, Bamberg M, et al. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000;11:553-9.
168. Miller KD, Loehrer PJ, Gonin R, et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997;15:1427-31.
169. Schmoll HJ, Beyer J. Prognostic factors in metastatic germ cell tumours. Semin Oncol 1998;25:174-85.
170. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8.
171. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J Clin Oncol 1998;16:2500-4.
172. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumour : a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692-701.
173. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumours. J Clin Oncol 2005;23:6549-55.
174. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005;16:1152-9.
175. Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumours. Cancer 1990;66:2476-81.
176. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-6.
177. Droz JP, Ribrag V, Ghosn M, et al. Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumours. Prog Clin Biol Res 1989;303:739-47.
178. Mardiak J, Salek T, Sycova-Mila Z, et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumours: a phase II study. Neoplasma 2005;52:497-501.
179. Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005;93:178-84.
180. Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumours: a matched-pair analysis. Ann Oncol 2002;13:599-605.
181. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumour patients. J Clin Oncol 2000;18:1173-80.
182. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003;21:4100-4.
183. Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumours: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007;25:2778-84.
184. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumours. N Engl J Med 2007;357:340-8.
185. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108-14.
186. Hartmann JT, Schmoll HJ, Kuczyk MA, et al. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumours. Ann Oncol 1997;8:531-8.
187. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006;24:5503-11.
188. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
189. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumours after cisplatin-based chemotherapy. Ann Oncol 1997;8:41-7.
190. Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumours. Multivariate analysis of risk factors and implications for management. Cancer 2002;95:520-30.
191. Oldenburg J, Alfsen GC, Waehre H, et al. Late recurrences of germ cell malignancies: a population- based experience over three decades. Br J Cancer 2006;94:820-7.
192. Rutherford EE, Ferguson JL, Geldart TR, et al. Late relapse of metastatic non-seminomatous testicular germ cell tumours. Clin Radiol 2006;61:907-15.
193. Spermon JR, De Geus-Oei LF, Kiemeney LA, et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002;89:549-56.
194. Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993;11:1300-5.
195. de Wit R, Sylvester R, Tsitsa C, et al. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non- seminomatous testicular cancer. Br J Cancer 1997;75:432-5.